IE 11 is not supported. For an optimal experience visit our site on another browser.

Inside the making of Biden's omicron playbook

The plan is rolling into motion nearly a year after his advisers weighed a bleak question: How would they deal with a hypothetical coronavirus strain that evaded vaccine protection?
Get more newsLiveon

WASHINGTON — Last year on Christmas Eve, advisers to President-elect Joe Biden held an emergency meeting to discuss a scenario that felt increasingly likely: the emergence of a mutant strain of the coronavirus that would evade vaccine protection.

At the time, the alarm bells were ringing for the alpha variant, which quickly faded. But the concerns led Biden’s team to lay the groundwork for the plan they are now beginning to implement as researchers work to determine how much of a threat the omicron variant may pose, according to people familiar with the planning.

While there are still more questions than answers about the variant, Biden administration officials are prepping for a litany of worst-case scenarios and daunting questions, such as: What would happen if it turned out that more than 200 million people needed to be revaccinated?

It will be several weeks before officials know the answer. So far, they have said it is possible that booster doses of the current vaccines will provide enough protection if the omicron variant turns out to be more lethal or contagious.

But until they know for sure, they are also counting on a system of genomic sequencing and testing that the administration has spent billions of dollars building out since Biden’s early days in office to help keep schools open and prevent the economy from enduring another shutdown.

“We are equipped and prepared to fight the omicron variant head on,” Dr. Rochelle Walensky, the director of the Centers for Disease Control and Prevention, told reporters Friday. “We are actively taking steps to stay ahead of the omicron variant.”

A central piece of the plan would be to quickly modify and manufacture new vaccines tailored to address a specific variant should the need arise. Since the early days of vaccination efforts, administration officials have been working with vaccine makers to ensure that the companies could rapidly reformulate the existing vaccines, get them through the regulatory process and begin mass production in months if needed.

The conversations went into high gear the week of Thanksgiving, when the first infections of the omicron variant were confirmed in South Africa, White House Covid coordinator Jeffrey Zients said.

“These conversations are happening as we speak in the spirit of being prepared for any scenario,” he said.

To ensure that the U.S. would still have enough vaccine supply, the administration included an option in a contract with Pfizer in July that would enable purchase of an updated version of its vaccine for a potential variant or a new formulation.

Pfizer and Moderna, which began working on an omicron vaccine last month, have already been through the process of reformulating their vaccines for the beta and delta variants, even though new vaccines were never needed for those strains.

They were able to make new vaccines for each variant but never brought the vaccines to market because the beta variant died off and the booster shots of the current vaccines appeared to be just as effective against the delta variant as a new delta-specific vaccine would have been.

If it is needed, the time to get a new vaccine to market could be less than 100 days, and new shots could be going into arms in the first quarter of 2022, said Andy Slavitt, who was a top White House adviser on the pandemic through June.

“The good news is in the event new formulations were needed, with the mRNA vaccines, you can change the production to a new vaccine on a dime,” Slavitt said.

But he said boosters are also likely to protect against the new variant, meaning the biggest task might be to persuade the 100 million people in the U.S. who have yet to get their boosters to line up for third shots in the weeks ahead.

Health officials said that even if it is determined that previously vaccinated people need to be revaccinated, they aren’t anticipating a return of the spring's mass vaccination centers and long wait times for appointments. There are now 80,000 retail pharmacies and health care providers set up to provide vaccinations, and the distribution, storage and manufacturing kinks of the early days have been worked out.

“We know what works. I mean, we literally have the written plans, staffing strategies, agreements or arrangements in place,” said Jim Blumenstock, the senior vice president for pandemic response and recovery for the Association of State and Territorial Health Officials. “The playbook is there. It's an issue of just having enough stamina and resources, heaven forbid, if we had to repeat the whole campaign again.”

Despite nearly a year of planning for the worst, the administration’s response hasn’t been without hiccups. The U.S. was slightly behind other countries in banning travel from the southern African countries where the variant was believed to be most widely circulating. The administration waited a week to change a testing window for international travelers from 72 to 24 hours while officials internally debated the need for stricter travel requirements.

And there are still holes in the ability to respond, starting with the limited supply of rapid tests that can be done at home and provide results in minutes, Blumenstock said. He said state officials repeatedly say they don’t have enough supply to meet the demand for the rapid tests, which is only growing as public health experts urge more people to rely on the tests if they are having mild symptoms, around times they are traveling or before they attend indoor gatherings.

Administration officials have been working for months to try to fill the hole, including spending more than $3 billion in the fall on at-home tests for food banks, health centers and schools — an investment that was also intended to push the test makers to ramp up the scale of production. The U.S. is on track to have 200 million to 500 million at-home tests available every month.

Biden said this month that the federal government would require health insurers to reimburse people for at-home tests as they would for laboratory tests, although the process for patients to submit claims for the tests and wait to get reimbursed stands to be cumbersome. For those without insurance, the administration will donate 50 million tests to community health clinics.

The administration is also relying on the network of genomic sequencing it has built up to be able to detect concerning variants and hopefully isolate people infected with them and their close contacts. The U.S. has gone from sequencing about 8,000 samples per week at the start of the year to 80,000 samples per week, about 1 in every 7 positive PCR test results.

The first case in the U.S. was identified through genomic sequencing at the University of California in a laboratory that is funded by the CDC using dollars from the Covid relief plan Biden pushed pass in the spring.

“The rapid turnaround and sequence analysis is an example of the importance of our investments this year to expand genomic sequencing across the country,” Walensky said Friday, “and to build a system that is prepared to swiftly respond to new and emerging Covid variants.”

CORRECTION (Dec. 12, 2021, 9:45 p.m. ET): A previous version of this article misstated when President Joe Biden said the federal government would require health insurers to reimburse people for at-home Covid-19 tests. He made the announcement Dec. 2, not last week.